| AGENUS INC. DL-,01 |
| USA |
| Gesundheit |
| US00847G8042 / A403RK |
| AJ8 (Frankfurt) / AGEN (NASDAQ) |
| FRA:AJ8, ETR:AJ8, AJ8:GR, NASDAQ:AGEN |
| - |
| https://agenusbio.com/ |
|
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies to treat cancer and infectious diseases. The company specializes in activating the body's immune system through advanced therapeutic approache..
>Volltext.. |
| 113.12 Mio. EUR |
| 390.48 Mio. EUR |
| 99.24 Mio. EUR |
| -9.17 Mio. EUR |
| 0.1 Mio. EUR |
| -0.29 EUR |
| 291.03 Mio. EUR |
| 2.61 Mio. EUR |
| -67.08 Mio. EUR |
| 0.01 |
| -2.72% |
| - |
| - |
| - |
| - |
| - |
| AGENUS |
| 31.03.26 |
|